Primary Category:
Treatment Protocols
Disease Category:
Renal, Renal Metastatic
Status:
Closed
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
NCT#02761057
Effective December 15th, 2019, study S1500 is permanently closed to accrual.
